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Abstract
Background: Oncopanel genomic testing, which identifies important somatic
variants, is increasingly common in medical practice and especially in clinical trials.
Currently, there is a paucity of reliable genomic reference samples having a suitably
large number of pre-identified variants for properly assessing oncopanel assay
analytical quality and performance. The FDA-led Sequencing and Quality Control
Phase 2 (SEQC2) consortium analyze ten diverse cancer cell lines individually and
their pool, termed Sample A, to develop a reference sample with suitably large
numbers of coding positions with known (variant) positives and negatives for
properly evaluating oncopanel analytical performance.
(Continued on next page)
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Results: In reference Sample A, we identify more than 40,000 variants down to 1%
allele frequency with more than 25,000 variants having less than 20% allele frequency
with 1653 variants in COSMIC-related genes. This is 5–100× more than existing
commercially available samples. We also identify an unprecedented number of
negative positions in coding regions, allowing statistical rigor in assessing limit-of-
detection, sensitivity, and precision. Over 300 loci are randomly selected and
independently verified via droplet digital PCR with 100% concordance. Agilent
normal reference Sample B can be admixed with Sample A to create new samples
with a similar number of known variants at much lower allele frequency than what
exists in Sample A natively, including known variants having allele frequency of
0.02%, a range suitable for assessing liquid biopsy panels.
Conclusion: These new reference samples and their admixtures provide superior
capability for performing oncopanel quality control, analytical accuracy, and validation
for small to large oncopanels and liquid biopsy assays.
Introduction
Recent Sequencing and Quality Control Phase 2 (SEQC2) [1] consortium efforts have
engaged in determining samples and methods for DNA-based NGS testing for a variety
of translational and precision medicine applications. Reported here from SEQC2 con-
sortium members are methods and archetypes suitable for establishing a reliable, ro-
bust, continuous, and generally available genomics reference samples that can be used
for assessing analytical performance of next-generation sequencing (NGS) assays across
a wide range of testing scenarios, especially in cancer and including those involving
regulatory science and precision medicine.
Genomic testing of tumors to determine important somatic variants in cancer is be-
coming more commonplace in medical practice and especially in clinical trials. Cur-
rently, there is a paucity of reliable genomic reference samples that can be used as a
standard across a wide range of genomic testing methods for assessing the potential ac-
curacy and the overall analytical performance of a given assay. The National Institute
for Standards and Technology (NIST) has developed several cell lines of reference ma-
terial for testing population genetics, which translates into a very high percentage of
variants inherently at 50% and 100% allele frequency in germline cells [2]. However,
these samples are not appropriate in their current form for comprehensively evaluating
the analytical performance of cancer panels as somatic mutations often at lower than
20% variant allele frequency (VAF). Other samples including reference standards devel-
oped for somatic mutation typically involve at most one cancer cell line and a matching
normal, greatly limiting the number of relevant variants at low VAF available for evalu-
ation [3–6]. While these reference standards are valuable and provide utility in several
NGS contexts, proper comprehensive assessment of cancer panels typically requires
more than 100 appropriate qualitative analytes (such as a variant detected/not detected)
in each of several distinct VAF ranges, which is more than what many general and
commercially available reference samples have in total. Finally, the overall variant de-
tection performance is inversely related to the VAF of the analytes targeted. To deter-
mine panel performance at different VAF magnitudes, reference samples should have
large numbers of variants at various VAF magnitudes.
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Commonly available commercial reference samples typically have less than 100
variants in a relatively small number of genes with allele frequencies suitable for pan-
cancer panel validation. More recently, Horizon Diagnostics released the OncoSpan
reference standard with 386 variants across 152 (114 COSMIC tier 1) genes [7]. Acro-
metrix released the Oncology Hotspot Control which has 555 variants across 53 (52
COSMIC tier 1) genes [8]. As useful as each of these reference samples are, even if both
are used in panel testing validation, only 127 out of the 576 COSMIC Tier1 genes will
have at least one variant in either panel and only 53 genes would have any variant from
a COSMIC Tier 1 gene with a VAF less than 20%. Large cancer panels, such as the Illu-
mina TruSight Oncology 500 (TSO500) panel, would only have a minority of genes
(121 genes total or less than 25% of TSO500) that could be tested within the panel.
With regard to the greater human exome, current reference samples including the
NIST Genome-in-a-Bottle (GIAB) references provide too few variants per gene (typic-
ally ~ 1 variant per gene in coding regions) and only at high VAF (~ 50% and ~ 100%).
Using NIST or similar reference standards for oncopanel testing would require poten-
tially complex admixtures of several distinct samples to create a wide range of variants
at various VAF ranges, a complicated process for even experienced laboratories.
Current needs in genomics testing are not limited to additional appropriate refer-
ence samples but also include describing appropriate methods and guidelines for
developing and verifying such a sample. Given the complexity and the magnitude
of the number of variants required for a reference sample, it is straightforward to
conclude that the most efficient development method is to make use of more easily
identified germline variants that are diluted in some fashion to resemble somatic
changes. This is reasonable as germline variants originated as a founder mutation
and assessing analytical performance of an assay can be independent of the bio-
logical impact of the variant.
The SEQC2 consortium, led by the Food and Drug Administration (FDA), is a con-
tinuation of successful prior efforts in examining methods and reproducibility in gen-
omics and transcriptomics [9–13]. The Oncopanel Sequencing Working Group within
SEQC2 was challenged with examining the reproducibility, sensitivity, and accuracy of
current (or in development) commercially available pan-cancer tumor panels for both
solid tumors and for liquid biopsies. We ascertained the need to (1) identify “ground
truth” of an unprecedented number of low VAF variants and invariant positions in a
DNA reference sample and (2) utilize the crowdsource effort of the SEQC2 consortium
to undertake massive data generation, management, analysis, and compilation of re-
sults. To that end, genomic DNA samples from ten cancer cell lines historically used to
create RNA for the Agilent Universal Human Reference (UHR) RNA sample [14] were
examined individually as well as in pooled form (termed “Sample A”) to develop a ref-
erence set (positives and negatives) for use with tumor cancer panels (Table 1). Fur-
thermore, a cell line derived from a normal male individual (Agilent OneSeq Human
Reference DNA, PN 5190–8848) (termed “Sample B”) was similarly characterized serv-
ing primarily as a negative control for somatic variants but also providing a genomic
background for mixtures between the two reference samples. In particular, we used
Sample B to dilute mutually disjoint variants in Sample A to a much lower VAF. Thus,
the pooled Sample A used in tandem with Sample B are suitable for panel develop-
ment, panel validation, and for quality control (high number of known positives and
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negatives) in parallel with an operational assay, allowing testing of large numbers of
variants across a wide range of allele frequencies.
Results
Identification of positives and negatives in the reference sample
This study utilized four different whole exome sequencing (WES) enrichment kits and
one whole genome sequencing (WGS) method: (i) Roche MedExome [15] (WES1), (ii)
Integrated DNA Technologies (IDT) xGen [16] (WES2), (iii) Agilent SureSelect [17]
(WES3), (iv) Thermo Fisher AmpliSeq Exome [18] (WES4), and the 10X Genomics
linked-read WGS sequencing [19] (WGS1). Details of the experimental design are
shown in Fig. 1. Replicate libraries were created by independent labs for each individual
cell line and sequenced to high depth for WES1–3 methods (WES deduplicated librar-
ies had a typical depth of 235× with an average depth range from 151× to 402× in their
targeted regions). WES4 and WGS1 were sequenced at lower depth without library rep-
licates (the typical depth was 148× for WES4 with a range across cell lines of 116–185×
while the average depth for WGS1 ranged from 64.5× to 74.9× across cell lines). As
these 10 cell lines were to be pooled together, we sequenced each cell line to sufficient
depth to ensure high sensitivity to detect variants above 10% VAF by cell line, which
would generally result in a collection of identified variants down to 1% VAF in the
pooled Sample A. Details related to the sequencing of the individual cell line libraries
and their read characteristics are shown in Additional file 1: Table S1.
FASTQ files from these libraries were provided to the working group participants for
variant calling by an assortment of bioinformatic pipelines (each site ran only pipelines
for WES or WGS data for which they were proficient). We created a reference bed file
that was the intersection of the design bed files of each enrichment kit (termed the
Table 1 List and description of 10 cancer cell lines and a normal reference cell line with %
estimated copy number alterations (CNA) and an intra-tumor heterogeneity (ITH) value to indicate
potential polyclonality of the cell line
Cell
line






Normal ~ 0 0
BLY B
lymphocyte
Myeloma Mixed with TLY within studyb ~ 25% 43.2
BRA Brain Glioblastoma Polyclonal 90% 21.0
BRE Breast Adenocarcinoma Polyclonal 60% 100.0
CRV Cervix Adenocarcinoma Polyclonal 70% 10.9
LIP Soft tissue Liposarcoma 90% 3.5
LIV Liver Hepatoblastoma 27% 2.5
MAC Macrophage Lymphoma Polyclonal 80% 11.8
SKN Skin Melanoma 24% 0
TES Testes Carcinoma 72% 4.8
TLY T
lymphoblast
Leukemia Inherently tetraploidc with
variations
22% 1.1
a CNA were estimated using Agilent GenetiSure Cancer Research CGH + SNP Microarray (2 × 400K), G5975A and WES
b Information of the mixture of the original BLY with TLY is provided in Supplementary Information
c Establishment of the tetraploid nature of the TLY is provided in Supplementary Information
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“Interval4” bed file) so that evaluation of the putative variants would potentially have
representative data from all four exome enrichment kits as well as WGS. The design
size of the regions-of-interest (ROI) of each kit relative to the known exome and their
overlap are provided in Additional file 1: Table S2. Variant calling methods, which in-
cluded GATK Haplotyper [20], FreeBayes [21], Mutect1 and Mutect2 [22], Platypus
[23], Samtools [24], Sentieon TNscope [25], VarDict [26], VarScan [27], and Somatic-
Seq [28], were combined with different alignment strategies (bwa-mem [29], bwa [30],
bowtie2 [31], etc.) to create a comprehensive set of putative variants. An overview of
each bioinformatic pipeline and WES kit combination is provided in Additional file 1:
Table S3.
To protect against a common bias towards false positive calls, the variant calls were
filtered based on NIST high-confidence or benchmark regions [2] [“Methods” section:
NIST high-confidence regions (v3.3.2 benchmark regions)] as well as identified low
genomic complexity regions [32] that resulted in a consensus target region (CTR) as
shown in Fig. 2. Within the CTR, a region that is roughly two thirds the size of the hu-
man exome coding regions, a set of known positive variants (termed Class 1 variants)
were identified as being called in the majority of the consortium pipeline-library combi-
nations for at least one cell line in each replicate of WES1, WES2, and WES3 (the repli-
cated kits). More details are available in “Rules for determining positive variants” in the
“Methods” section.
To further enrich the set of identified variants in important genomic regions, we also
examined each cell line using the WGS1 linked-read method in COSMIC genes [33,
34]. We added 359 variants (termed Class 2 variants) to our set of Class 1 variants that
were outside our CTR region but were in high-confidence coding regions of COSMIC
genes. The Class 2 variants were included only if they were detected by WGS1 in at
Fig. 1 Overall flow diagram of process/method. Discovery of Class 1 variants came from consensus analysis
of WES1/2/3/4 runs on overlapping WES kit target regions having high confidence. Additional Class 2
variants were discovered after analyzing WGS1 with WES results. Variants were confirmed by analyzing in
silico A results where we combined individual BAMs from each cell line replicate and by analyzing merged-
BAM Sample A from pooled Sample A individual replicate BAMs. Finally, a subset of these variants was
orthogonally validated with ddPCR
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least one cell line by two different variant calling methods and detected by at least two
WES kits. From Table 2, we see that over 10% of the identified variants having VAF <
20% in COSMIC genes are Class 2 even though they represent < 1% of positive vari-
ants overall. Using hg19, we identified 42,570 Class 1 and Class 2 variants in Sample A
(28,064 having VAF less than 20%) with additional characteristics of these variants pro-
vided in Additional file 1: Table S4. Notably, 1653 variants are in COSMIC genes with
< 20% VAF.
Pile-ups of each cell line were also examined to identify 10,229,649 negative variant
loci (hg19) that were lacking any variant in the pooled Sample A (more details provided
in “Rules for determining known negative variant positions”). Negative loci for pooled
Sample A imply that if there is any somatic variant at those loci, it must have an ob-
served AF at less than 0.25% in the pooled Sample A for each replicated kit.
To confirm these individual cell line results, we constructed independent triplicate li-
braries of the pooled Sample A using three of the original four WES kits (Roche
MedExome, IDT xGen, Agilent SureSelect) and sequenced each library very deeply
(deduplicated average depth of 180–580× depending on library) as shown on the right
side of Fig. 1. The detailed sequencing QC statistics of pooled Sample A are shown in
Additional file 1: Table S5 with a summary in Additional file 2: Fig. S1. Using Somatic-
Seq, we confirmed greater than 99.5% of the Class 1 and 2 variants identified from the
individual cell line analysis were at or near the expected VAF in Sample A using either
an in silico version of Sample A or the merged-BAM Sample A. SomaticSeq also con-
firmed 99.96% of all variants in some fashion from either individual cell lines, the
merged-BAM Sample A, or the in silico version of Sample A (see Additional file 1:
Fig. 2 Defining the consensus target region (CTR). The regions shown are not to scale. Most of these
regions and their sizes are provided in Additional file 1: Table S2. The low complexity regions are excluded
from the CTR. Importantly, the size of the CTR is ~ 22.7 Mb for hg19
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Table S6a. A merged-BAM of Sample A for a particular kit is a merging of the three in-
dependent replicate library deduplicated Sample A BAM files for each of WES1–3. The
in silico version of Sample A is a merging of the deduplicated cell line libraries for each
of WES1–3. We should note other pipelines besides SomaticSeq were also highly sensi-
tive to the identified variants and exemplar results for certain combinations of pipelines
and kits are shown in Additional file 1: Table S6b. In addition, although the WES4
Thermo Fisher runs had only one library per cell line and were not as deeply sequenced
as WES1–3, over 97.8% of the CTR positives with Sample A VAF greater than 5% were
detected in at least one cell line. Additional information on WES4-related sensitivity
and precision of individual cell lines are provided in Additional file 2: Fig. S2.
Finally, we used droplet digital PCR (ddPCR) technology to orthogonally verify 284
positives and 39 negatives randomly chosen with stratification using different classes of
variants in individual cell lines, reference Sample A, and normal Sample B. We also or-
thogonally tested those same variants using admixture reference samples C, D, and E
where Sample C is a 1:1 dilution of A:B, Sample D is a 1:4 dilution, and Sample E is a
1:24 dilution. The verified variants included more difficult-to-detect variants such as 50
smaller insertions-deletions (indels), 35 of which had VAF < 10% and 95 other low-
frequency variants (VAF < 5% in pooled Sample A) including 12 low VAF Class 2 SNVs.
We also verified 20 variants that were under copy number (CN) influence (i.e., loci hav-
ing detected CN changes in at least one of the 10 cell lines). While we identified a small
number of variants near homopolymer regions (less than 0.1% of the total), we did not
Table 2 Variant characteristics of Sample A compared to other reference material (Sample A




























genes with 1 or
more variants
(Tier1/Tier2)
Sample A 42,570 42,570 2432 28,064 1653 12,238 422/102
SNV 42,021 42,021 2398 27,683 1624
Indel 549 549 34 381 29
Acrometrix 555 555 555 341a 341a 53 52/1
SNV 504 504 504 317 317
MNV/
Indel
2/49 2/49 2/49 0/24 0/24
Oncospan 386 386 319 52 46 152 114/2
SNV 357 357 297 43 38
Indel 30 30 22 9 8
HCC1395
(somatic)
41,556 487 193 144 14 466 188
SNV 39,536 460 186 132 13
Indel 2020 27 7 12 1
HCC1395BL
(germline)
3,577,254 21,755 NA NA NA 9566 NA
SNV 3,225,512 21,381
Indel 351,742 374
aMost of the Acrometrix variants are synthetic controls. Thus, it is possible to construct a version of the material where
524 of the 555 variants have a VAF < 20%
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verify those variants independently using ddPCR but did ensure that all variants near
homopolymer regions and having VAF above the limit of detection of linked-read
WGS were detected by the linked-read WGS. Additional file 1: Table S7 provides a de-
tailed breakdown of the classes and subclasses and the number of variants by class or-
thogonally validated by ddPCR.
For the putative positives tested by ddPCR, 100% of the variants from the different
classes were verified as positives with 99.65% having a concordant VAF value (i.e.,
within stochastic sampling noise) when comparing ddPCR and WES consensus VAF
estimates for the individual cell lines and for Sample A (Fig. 3a, b; r2 = .994 on linear
and r2 = .97 on log scale respectively). In addition, variants with VAF diluted through
admixture changed in expected and predictable ways in concordance with the dilution
level (Fig. 3c). For Samples D and E (the samples having the identified positive variants
but at lower frequency), we also examined the concordance of replicate ddPCR wells
along with concordance of the same variants in replicated Sample B assays (where no
detection is expected). Figure 3d shows r2 = .95 for log (VAF) in replicate runs of Sam-
ples D and E and also shows uncorrelated VAF of those same variants in replicates of
Sample B where they should not be present. In general, about half of the ddPCR assays
showed noticeable variation between 0.1 and 0.01% VAF in Sample B for loci expected
to be variant-free in Sample B, implying that the observed VAF is mostly background
measurement error in ddPCR. This implies the positive variants are verified down to
0.1% in all reference samples but not necessarily below 0.1%. Negatives have the oppos-
ite characteristic: we are confident that the true VAF for each negative locus tested by
ddPCR, if greater than 0, is below 0.1% VAF.
From this process, we identified 42,570 (hg19) and 38,957 (hg38) variants and more
than 10,000,000 negative loci in the autosomal coding regions of the human genome
for Sample A. We also identified 13901/12623 (hg19/hg38) positives for Sample B.
Hg38 positives are noticeably less in number due to the requirement that positives be
in NIST high-confidence (benchmark) regions for that reference version combined with
over 2000 Sample A positives identified in high-confidence regions of hg19 not being
in high-confidence regions of hg38 (even though the hg19 variants are easily mapped
to hg38). The majority (~ 70%) of Sample A variants have a VAF below 20%. Of these
42,570 hg19 variants, 1809 were identified in COSMIC Tier 1 genes with 1255 having a
VAF below 20%. The overwhelming majority of positives (98.7%) consist of single nu-
cleotide variants (SNVs) with indels as a minority (1.3%) across the exome. Some de-
tails and characteristics of the variants identified from Sample A are provided in
Table 2 relative to other reference samples.
An illustrative example of the various design considerations, constraints, and infor-
mation available (including positive and negative variant positions, WES kit interroga-
tion regions and their overlaps, high-confidence regions, CTR) from this study is
provided with a representative gene (TP53) in Fig. 4.
To maximize the number of variants with a wide range of VAF, we selected several
diverse cell lines derived from distant individuals. These cell lines represented a variety
of cancer tissues having been previously selected to compose the Agilent UHR RNA
[14]. Further, we used a very well-characterized cell line from a normal individual
(Sample B) to dilute the VAF for the majority of variants in reference Sample A to cre-
ate reference samples C(1:1), D(1:4), and E(1:24). However, one could create a different
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reference sample using other cell lines. For more detailed recommendations and infor-
mation related to creating a reference sample with low allele frequency variants, includ-
ing the impact of the number of cell lines to admix, see Additional file 3:
Supplementary Information section “Recommended process for reference sample
creation.”
Characteristics of reference Sample A and the cell lines than comprise it
The cell lines examined and pooled for reference Sample A are diverse in several ways.
In addition to being reflective of different tissues of origin, they also are reflective of
some degree of genetic diversity as they contain germline variants from 10 distinct indi-
viduals. In fact, most variants identified are germline variants as cancer cells typically
have less than 10 mutations per Mb of coding sequence while typical germline variants
may be on the order of hundreds per Mb of coding sequence. The number of variants
positively identified for each cell line (including Sample B) is provided in Additional file
1: Table S8.
Fig. 3 ddPCR and WES concordance: a VAF concordance of individual cell line WES consensus results with
ddPCR assays of that cell line. b Concordance (log10 scale) of Sample A VAF between ddPCR and WES for
positives only. c Various dilutions (C, D, E) of Sample A into B achieve the expected reduction in VAF as
seen in the ddPCR results. It also shows the potential noise for measuring ddPCR variants below 0.1%
(10− 3) in the distribution of Sample B variants. d Concordance of replicate ddPCR assays (on log10 scale) is
very high (r2 = .95) in diluted target Samples D and E. Putative VAF values from Sample B are also shown
for comparison
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Population ancestry and the number of somatic variants are the primary cause of
variation in magnitudes of SNVs and Indels across cell lines. The TLY cell line itself
has roughly 19k variants (including by far the most identified somatic alterations, pos-
sibly numbering over 6000). In addition to TLY having many somatic variants, TLY is
also essentially tetraploid with some variations (Additional file 2: Fig. S3). Other charac-
teristics of the cancer cell lines include a high degree of structural variation. Some cell
lines have more than 50% of their genome impacted by somatic copy number alter-
ations (sCNA) while all are estimated to have at least 22% of their genome impacted by
sCNA (Table 1). Two cell lines, BRA and LIP, have apparently greater than 90% of their
genome impacted by sCNA. In addition to structural variation, there are also polyclonal
aspects to some cell lines. For example, BRA, BRE, and LIP cell lines are considerably
polyclonal while LIV, MAC, and TES are much less so. Values of intra-tumoral hetero-
geneity [35] that support this assessment are also provided in Table 1.
Finally, we cross-referenced the 42,570 Sample A positives with ClinVar and Hot-
spots databases to see how many variants were potentially pathogenic and thus of great
consequence. From Additional file 1: Table S9, we see that Sample A contains at least
58 pathogenic variants (50 from ClinVar and 13 from Hotspots). Some of these variants
are well known such as the BRAF V600E variant and the NRAS G12C variant.
Variant allele frequencies of the individual Universal Human Reference cell lines and the
resulting pooled Sample A
VAF values of the identified variants within each cell line are an important characteris-
tic and play a primary role alongside of variant commonality between cell lines in de-
termining the resulting VAF in the pooled Sample A. Of tertiary importance is whether
Fig. 4 Illustration of considerations for determining positives and negatives within the reference material.
Each WES kit coverage is shown relative to their intersection with coding regions (Interval4), the high
confidence region, and the low complexity region. Also shown are known positive variant positions in
Sample A (mostly Class 1 variants SNVs) including one identified by a violet box that is outside the Interval4
and CTR regions (Class 2 variant). Other positions shown include known negative positions
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a particular variant in a cell line is in a region having large copy number deviations
from the normal diploid state. In theory, unshared variants in individual cell lines that
are heterozygous should result in a VAF of approximately 5% in pooled Sample A while
homozygous unshared (between cell lines) variants should result in a VAF of approxi-
mately 10% in A. From Fig. 5a, the observed VAF from pooled Sample A is in the range
of 0 to 20% where ~ 70% of the Class 1 and Class 2 variants are observed.
From the histogram, there is a notable overall mode around 5% but no local mode
around 10%. The likely reason for the lack of a local mode at 10% is that any germline
variant that is homozygous in one cell line is most likely a high frequency population
variant and therefore would likely be present in other members of the same population,
causing the resulting VAF in a pooled sample like Sample A to be greater than 10% de-
pending on the variant’s population frequency. The VAF distribution of normal Sample
B (Fig. 5b) reflects the hetero-homozygous dynamic that we expect as well as a nearly
total deficiency of variants that have VAF up to 40% or are between 60 and 95% due to
the (as expected) near absence of somatic point mutations and copy number variants.
While Fig. 5a provides the VAF distribution of all variants (Class 1 and Class 2), they
are dominated by the presence of Class 1 variants (> 99%). Additional file 2: Fig. S4
shows the distribution of the Class 2 variants in Sample A. Although the distributions
are similar, the Class 2 variants show a slightly smaller percentage of their variants hav-
ing VAF < 20% in Sample A (58% of all Class 2 variants vs. 66% overall). The histo-
grams of VAF of each individual cell line that constitutes Sample A are provided in
Additional file 2: Fig. S5a-j. One can see evidence of CNA in the VAF histograms for
most cell lines. Similarly, histograms of VAF of each individual cell line for Class 2 vari-
ants in Sample A are provided in Additional file 2: Fig. S5k-t.
We investigated the potential amount of bias in individual VAF estimates that may
be associated with each kit and may be a unique characteristic with certain variants.
Bias in VAF can arise from several factors: bait-hybridization bias, mapping errors and
bias in mapping towards the reference genome [36], and confusion in calling a multiple
nucleotide polymorphism or a complex multi-allelic polymorphism. To separate map-
ping and calling issues from bait biases, we ran several individual pipelines including a
compendium method (SomaticSeq) for each kit of pooled Sample A replicates as well
as in silico Sample A and merged-BAM Sample A (see “Methods” for details). In silico
Sample A for each enrichment kit was based on equal overall read depth by cell line of
BAM files accumulated across Sample A’s components and then calling variants based
on the 20× larger BAM (as each cell line had two replicate library results). Merged-
BAM Sample A was a merging of the three independent library sequencing BAMs (by
kit) and then calling variants on the roughly 3× larger BAM relative to an individual li-
brary BAM. In each case, either result helped overcome sampling variation and other
variation (such as variation in CN state across cell lines) to provide a less variable VAF
estimate for pooled Sample A. Additional file 2: Fig. S6 is a plot matrix that illustrates
the high level of concordance that the raw Sample A VAF average, in silico Sample A
and merged-BAM Sample A VAF estimates have with each other as well as across
WES kits. The correlation between and among kits for Sample A is equal to or exceeds
0.996 in all cases with the variation around the expected 45-degree line in the range of
0.05–0.10. We also observed a similar consistency across kits with correlation exceed-
ing 0.987 between any two distinct kits whether cell line averages, in silico or merged-
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BAM results. For final VAF values for binning purposes to evaluate panel performance,
we used merged-BAM estimates averaged across the kits (see “Methods” for more de-
tails). From Fig. S6, little differential bias appeared in VAF estimates between WES kits.
However, there are most likely common biases that exist for most capture-bait enrich-
ment techniques overall (see more details in the section Additional file 3: Bias in re-
ported WES allele frequencies).
In addition to concordance in VAF estimates across kits, we also observed
general concordance between kits in straightforward detection of the variants of
Fig. 5 a VAF histogram of Sample A variants (Class 1 and Class2) with the obvious large numbers of
variants in the low VAF range from 0.01 to 0.10. b VAF histogram of normal Sample B which can be used to
dilute variants from Sample A
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Sample A using only one bioinformatic pipeline: SomaticSeq. Additional file 2: Fig.
S7 illustrates the agreement among kits among variants in the CTR whether one
examines the Merged-BAM Sample A construct or the in silico Sample A from
Fig. 1. The vast majority (96%) of positives were detected in all three WES1-WES3
kits in both merged-BAM and in silico Sample A using the single pipeline. When
we examined the potential reasons for variants identified in only one or two kits,
we observed that undetected variants were typically from lower-depth libraries or
lower-depth ROIs from the library. Therefore, our conjecture is that one can iden-
tify the great majority (> 90%) and estimate the total number of potential positives
for a particular candidate reference sample using one kit with three independent li-
brary replicates of the pooled sample with sufficient depth combined with an ad-
vanced variant caller such as SomaticSeq.
We examined the variant and variant allele distributions by chromosome, by type
(Indel vs. SNV) and by VAF range. Additional file 1: Table S10 provides a general view
of the frequencies of identified indels vs. SNVs by chromosome and of how many vari-
ants by chromosome are in different VAF ranges: 1–2.5%, 2.5–5%, 5–10%, 10–20%,
20–50%, 50–100%. Some unusual characteristics of the cell lines that we perceived
from the table include the large number of low-frequency variants seen for chr11 and
chr16 compared to peers and the inordinately high number of variants in the 2.5–5%
range for chr19 in the TLY cell line.
Examination of data from individual cell lines allowed for identification of potential
issues such as cell line contamination, pooling errors, or pooling imbalances. In fact, in
the initial creation of DNA for cell line BLY, TLY was inadvertently admixed with BLY
in a 2:1 M ratio prior to the creation of pooled sample A and the admixtures C, D, and
E. The consortium recognized this admixture early on when analyzing the individual
cell line WES results. For example, we noticed the following relationships between the
TLY and BLY DNA samples received:
(a) The major copy number alterations (CNA) of TLY were also observed in the BLY
mixture (Additional file 2: Fig. S8)
(b) 95% of the detected variants including more than 1000 somatic variants in TLY
were also detected in the BLY mixture. We did not observe 100% detection as TLY
had many low allele frequency variants that, when diluted into BLY DNA, enabled
them to elude detection at study-related sequencing depths of individual cell lines.
This admixing implied that regions from the DNA initially labeled as BLY and
having variants unique to the original cell line of BLY would be underrepresented
in the pooled Sample A. Similarly, variant regions for variants unique to TLY
would be overrepresented, implying that variants unique to BLY and TLY would
not necessarily have a VAF in the pool equal to roughly 1/10 their frequency in
the individual cell line. However, due to sometimes large CN alterations in other
cell lines, this property was not unique to BLY and TLY. In the end, we deter-
mined that the pooled reference (Sample A) itself provided the best estimate of the
pooled VAF through direct interrogation as the pool naturally subsumes positional-
dependent depth variation across cell lines. As the final estimates of VAF for Sam-
ple A are based on the direct testing of Sample A itself, the inadvertent admixing
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of BLY and TLY when creating DNA for the BLY cell line had minimal final
impact.
Discussion
One primary challenge in oncopanel validation is to have appropriate reference samples
to gauge the true performance characteristics of a test. This evaluation must often
cover various aspects of performance that are beyond simple summaries of binary data
(detected/not detected). Panels themselves can range from testing a few thousand loci
to tens of millions. This variety creates complexity related to characterizing assay per-
formance as the LOD for a given analyte may be variable based on the locus and vari-
ant type. For example, it is well known that SNVs are easier to detect (higher recall/
sensitivity) than small indels, which in turn are easier to detect than larger indels re-
gardless of the VAF. Moreover, for each variant type, generally those variants having
higher VAF are easier to detect than those with smaller VAF. To address these require-
ments, organizations have often historically used bespoke mixtures of their own in-
house or artificially constructed specimens combined with limited publicly available
reference samples to develop, evaluate, and validate their DNA assays. However, the
custom nature of these samples outside of typical GMP-level manufacturing leads to
questions regarding reliability, bias, and stringency of the sample and the testing. We
believe that a proper reference sample from a vendor who has proficiency with building
these samples will improve the quality and trustworthiness of oncopanel testing in
general.
We recognized early in the process that the reproducibility of identified variants be-
tween pipelines for the same initial FASTQ data sets were greatly improved if we fo-
cused on high-confidence regions of the genomes. These high-confidence regions, also
known as benchmark regions, were determined by NIST efforts in sequencing the
Genome-In-A-Bottle (GIAB) germline reference specimens, which were some of the
first reference samples for validating methods when detecting germline or population
variants. Additional file 2: Fig. S9 illustrates the unexpected VAF of a large percentage
of putative variants in Sample B that replicate in a distinct run when using positions
outside of high-confidence regions. As Sample B is from normal tissue, there should be
minimal loci influenced by CN or somatic changes creating loci with VAF in ranges
outside of VAF = .5 and VAF = 1. When restricted to high-confidence regions like the
CTR, aberrant variants can constitute less than 1% of the total (whereas unrestricted
they may constitute more than 20% of the total). Therefore, we see that high-
confidence regions have a greatly reduced likelihood of false positive variant calls.
Lower confidence regions typically have one of the following characteristics: short re-
peat motifs, general low diversity or base complexity, or sequence similarity with other
regions of the genome. Calling variants with high accuracy and specificity in these more
challenging regions may require more than short-read technology. The technologies
utilized in our study were based on short reads as a primary backbone to achieve the
required depth for low allele frequency with reasonable cost. More importantly, short-
read technology is inherently compatible with liquid biopsy specimens which is charac-
teristically composed of small DNA fragments (~ 150b). Therefore, we restricted our
domain for the initial positive and negative variant set for Sample A to be within the
high-confidence human exome that was not of low complexity.
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While the consortium’s efforts have identified a reference sample with an unprece-
dented number of known positives in coding regions as well millions of negative loci in
one reference sample, the positive and negative set is not comprehensive and can be
enlarged in a variety of ways. For example, we did not examine introns and UTR re-
gions of genes even though a high percentage of the ROIs for various enrichment kits
have baits targeting these regions. There are well-known examples of important intron
and UTR variants, especially those variants impacting RNA editing or splicing [37].
One can also extend the identified variants in Sample A in COSMIC genes (and in
other genes) by possibly 50% by mining the lower confidence coding regions (high-con-
fidence regions are 63% of the bases of the human exome). However, one may need to
utilize longer-read technology at high depth with mostly intact DNA. We also initially
omitted examination of chromosome X and Y as mutations in these regions are fre-
quently more associated with developmental disorders and other non-cancerous dis-
eases even though some chrX genes are associated with cancer [38].
Some classes of variants are most likely underrepresented. In particular, the propor-
tion of identified indels to variants is only 1.3%, although this proportion is higher in
COSMIC genes, especially at low VAF. The SEQC2 Somatic Mutation Working Group
observed a 3× larger rate for indels [39] (4%) in their detailed analysis of a one breast
cancer cell line (HCC1395) and the GIAB consortium initially observed a 2.3% rate for
indels in NA12878 (a normal cell line) in the high-confidence regions of NA12878 (also
known as HG001). Still others have observed a much higher indel rate in whole exome
and whole genome analysis for other specimens (e.g., 12% [40], 13% [41]). However, it
is unclear how these ratios may differ considering high-confidence regions only. Al-
though we have identified more than 500 indels in Sample A, we recommend the Sam-
ple A reference be further investigated specifically for relevant indels, such as those in
COSMIC genes. Although relatively small in magnitude, indels are excellent phenom-
ena for challenging various mapping and variant calling methods. Therefore, expanding
the known indels in Sample A will provide a potentially less optimistically biased as-
sessment of the capability of panel assays in detecting indels in general.
Using hg19, the consortium identified 42,570 unique variants in pooled Sample A in
coding regions and 2432 (or 5% of the total) in COSMIC [42] Tier 1 and Tier 2 genes.
There are roughly 723 COSMIC Tier1 and Tier2 genes which is 3.4% of the total num-
ber of coding genes. The enrichment of identified variants in COSMIC genes is partly
due to our focus in finding Class 2 variants in COSMIC genes outside of the Interval4
region. In that effort, we identified 359 additional variants in COSMIC genes relative to
our initial Class 1 positive set. The Class 1 positives include 2073 variants from COS-
MIC genes which are 4.9% of the total of 42,211 variants in the Class 1 set. However,
the probable primary reason for COSMIC genes being enriched for variants is due to
selection bias in our reference sample (ten distinct cancer cell lines versus normal
cells).
The Sample A variant content compares favorably in magnitude and is complemen-
tary to other reference samples. As described previously, Table 2 provides a comparison
of the identified contents of Sample A versus Acrometrix and OncoSpan reference
samples by VAF range and by gene category (for COSMIC genes). For example, Sample
A contains at least one variant in 422 COSMIC Tier 1 genes, with 375 COSMIC Tier 1
genes having a variant at low frequency. By comparison, OncoSpan’s comparable values
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are 114 and 29 COSMIC Tier 1 genes respectively and Acrometrix’ comparable values
are 52 and 37 COSMIC Tier 1 genes respectfully (Note: Acrometrix can manipulate
their synthetic variants to be at lower VAF, if needed). Acrometrix concentrates their
variants into specific genes. For example, 145 of the 555 identified variants in Acrome-
trix are in four genes: TP53, PTEN, EGFR, and APC. However, only 42 of those 145
variants have a VAF less than 20% and all 42 variants with low VAF are in TP53 only.
That is, no variant in the standard Acrometrix controls for PTEN, EGFR, and APC has
a VAF less than 20% even though these three genes contain almost 20% of all identified
variants. In comparison, for the same genes, Sample A has less variants overall in these
four genes (31 vs. 145) than Acrometrix but over half of these Sample A variants have
a VAF less than 20%. Also, in Sample A, each of TP53, PTEN, EGFR, and APC have at
least one variant with a VAF less than 20%. OncoSpan’s identified variants are more
uniformly distributed over the OncoSpan gene set. However, OncoSpan’s relative con-
centration of variants is much lower than Sample A (0.2 variants per COSMIC Tier 1
gene for OncoSpan vs. 3.1 variants for Sample A). In short, all of these reference sam-
ples are useful when developing and validating panels. Acrometrix in particular with its
high proportion of variants concentrated in relatively few genes would be highly suited
for small fragment-based panels that overlap with its concentrated list (amplicon-based
panels may have challenges with the high concentration creating interference with
primers). OncoSpan and Sample A test variants in many more important COSMIC
genes. Sample A also tests variants throughout the human exome, averaging two vari-
ants for every gene and having 12,238 genes with at least one identified variant. Acro-
metrix and OncoSpan contents are focused on currently known actionable variants.
Sample A content, while containing many important and actionable variants, is more
designed for assessing analytical performance across a flexible target region for a wide
variety of potential genomic assays including clinical assays.
During the initial phase of discovering variants in Sample A, we examined data from
four different whole exome enrichment kits. When reviewing the sequenced data re-
sults, we realized that the data from the AmpliSeq WES4 panel was noticeably different
than the other three WES panels. In particular, the other panels tested technical repli-
cates for each cell lines while the WES4 results had only one singlet per cell line. The
WES4 results also had lower coverage per cell line which presented challenges in de-
tecting lower frequency variants in certain cell lines, especially the TLY and BLY cell
lines that had a higher concentration of variants at lower VAF values. We also had
many fewer pipeline outputs with WES4. Therefore, the WES4 results were used as an
independent confirmation of the positives derived from WES1-3 and WGS1 which all
used Illumina-based sequencing. We were successful in that 97.8% of the Sample A
positives having a VAF greater than 5% were detected by WES4. The gap is primarily
due to the lower depth of WES4 especially for BLY. However, we encourage the com-
munity to evaluate Sample A with other alternative sequencing technologies so that
omissions can be uncovered and any potential false positives, especially variants identi-
fied at the lower allele frequencies (less than 2%), can be identified.
The consortium made extensive use of the v3.3.2 NIST high confidence (benchmark)
regions from the ongoing GIAB project [2, 43, 44]. We examined the high-confidence
regions from five individuals: the female Caucasian (HG001), the Ashkenazim trio
(HG002-HG004), and the Chinese son (HG005) within a trio [2]. NIST has publicly
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provided well-annotated and defined high-confidence benchmark regions for detecting
small variants (SNVs and small Indels) for both hg19 and hg38 versions for their entire
genomes. We observed that the high-confidence regions for HG002-HG005 had greater
than 95% overlap (min X ∩ Y greater than 95% for X and Y ε HG002-HG005) for the
coding regions of the human genome. However, the high-confidence region for HG001
was noticeably different than the other four in terms of size: HG001 benchmark regions
were noticeably larger by 3–4% (even after excluding chrX regions exclusive to
HG001). Reasons for these differences are discussed in the section “NIST high-
confidence regions (v3.3.2 benchmarking regions)” in “Methods.”
We chose a more conservative approach for ground truth and created a common
high-confidence region based on overlapping regions of HG002, HG003, HG004, and
HG005 to serve as the basis for high-confidence regions for this initial release of posi-
tives and negatives. In addition, we excluded a small amount of low complexity regions
[32] overlapping with this more universal high-confidence region which served as the
basis for both Class1 and Class 2 variant detection. Although these benchmark sets
were developed for NIST sample-specific purposes, the consortium determined early
on that the reproducibility of variant calls in general was much greater within these
benchmark regions than outside. As we utilized the v3 NIST benchmark regions for
this release, it is more suited for use with panels employing shorter-read technologies.
As v4 benchmarks become available, this Sample A reference should be updated to be
more compatible with long-read methods [45].
From ddPCR analysis, we detected a small reference bias in the WES results. This
bias was largest in the middle of the dynamic range of variants measured in Sample A
[.01,1] and generally larger for indels than SNVs. We typically observed SNV VAF
values that were up to 7% relatively higher for ddPCR than that observed from the con-
sensus WES estimate. Indels could be as much as 15% relatively higher for ddPCR than
the WES estimate. For example, SNVs and indels observed at 10% VAF from WES
would typically be observed at 10.2 to 10.7% and 10.5 to 11.5% respectively from
ddPCR. Although this bias is rather small, it may have certain impacts for thresholding,
even at lower VAF thresholds when comparing results from orthogonal measurement
platforms. The bias can be most easily observed in Fig. 3a where biases in the indels
are clearly observable to the left relative to the other types of variants (especially near
VAF = .5 and 1). See Additional file 3: Supplementary information section “Bias in re-
ported WES allele frequencies” for more details.
When using a reference sample such as Sample A for cancer panel or liquid bi-
opsy performance evaluation as in companion efforts by the SEQC2 consortium
[46, 47], caution must be taken when performing the final evaluation. A large por-
tion of the low-frequency variants in Sample A originated as germline variants in
the original cell line. As some pipelines may automatically remove certain known
germline variants when identifying somatic changes, one may need to review fil-
tered results to properly account for putative false negatives. Otherwise, key met-
rics such as recall/sensitivity and precision may be greatly impacted. Likewise,
complex variants such as multi-allelic variants and multi-nucleotide variants
(MNVs) can pose challenges in both representation and proper assessment of per-
formance of solid tumor and liquid biopsy panels. Reference Sample A contains
both multi-allelic variants and MNVs. See the section “Complex variants including
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multi-allelic variants and multi-nucleotide variants (MNVs)” in “Methods” for a
more detailed discussion of these variant types in Sample A and techniques that
properly characterize them.
In addition, we implemented certain constraints to increase confidence in our nega-
tive positions as proving a negative is inherently difficult. Those constraints may omit
regions that are subject to systematic errors in targeted sequencing thereby potentially
causing an underestimate in the true false positive rate when using Sample A alone and
its identified negatives. Additional orthogonal sequencing technologies can potentially
be used to further expand the set of negative variant loci of Sample A so that system-
atic errors related to a particular technology or genomic region are not hidden. Com-
plementary alternative methods to estimating the false positive rate indirectly include
assessing the rate of low VAF loci in known normal cells (something that should not
exist). This method be unbiased relative to systematic sequencing errors that could
have biased our negative set for Sample A.
Reference samples or reference DNA are ideally produced using a large pool of such
DNA at one time so that aliquots will be a homogeneous and consistent resource for
several years. This was done for this study and this key practice has important ramifica-
tions. The cancer cell lines that constitute Sample A already have chromosomal remod-
eling and significant copy number alterations (CNA). As the cell lines go through
additional passages, more alterations and new variants could be reasonably expected.
Therefore, each new iteration of the resulting large DNA reference sample pool should
be thoroughly assayed to monitor and quantify changes, which will invariably occur
given the magnitude of relevant variants having low VAF in the reference Sample A.
Due to the different ploidies that occur within and between each cancer cell line, the
pooled Sample A is not as suitable a reference sample for detecting CN alterations,
even at the ploidy level. As we do not propose Sample A for this purpose, given the
creation of a large pool of DNA with verified variants, the main impact of variations in
ploidy levels are corresponding variations in observed depth levels of Sample A. How-
ever, the “natural” variation in the resulting library due to enrichment bait bias impacts
coverage depths in the final pool more noticeably in general than ploidy-level changes
in individual cell lines. Therefore, ploidy variation in the individual cell lines create no
worse variation in overall read depths in Sample A than what is already occurring due
to the nature of the bait-based WES assays (based on comparing the distribution of
read depths in variants common between the normal Sample B which only has bait bias
impacting local depth and Sample A which has both bait bias and ploidy variation—
data not shown). So long as new iterations of the cell lines and Sample A are properly
tested, we see no issue in updating the variant information for each iteration.
Conclusions
We have reported efforts by the SEQC2 consortium Onco-panel Sequencing Working
Group to address urgent needs in the regulatory science and precision medicine com-
munities regarding genomics reference samples. NGS is rapidly changing clinical care
in oncology, drug development, and regulatory science. The 21st Century Cures Act
sought to catalyze the development of new medical technologies when fundamental ad-
vances in our understandings of the genetic basis of disease and advances in medical
technology are allowing significant progress on previously vexing conditions.
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The two reference samples (Sample A and B) described in this document have an un-
precedented number of known positive variants and known negative loci down to a 1%
VAF. In particular, we have identified 42,570 distinct positive variants and greater than
10,000,000 negative loci in human exome coding regions. In reference Sample A, we
have identified 1653 variants in COSMIC genes with VAF between 1 and 20%, implying
on average more than two positive low allele frequency variants per COSMIC gene.
Sample A has, to our knowledge, the largest number of identified positive variants in
COSMIC genes: ~ 5-fold as many as the Acrometrix control, ~ 40-fold as much as
OncoSpan, 100-fold the amount in HCC1395) having low variant allele frequency
values [1–20%] for one reference specimen.
When combined with the normal Sample B reference genomic background or similar,
one can create a new reference sample that has ever decreasing lower ranges of VAF
for validating highly sensitive cancer panels or liquid biopsy assays. The Sample A and
B content verification utilized four different WES library prep methods having very
high levels of concordance. The study also used WGS to enrich known positives in
COSMIC genes which were not in common ROIs to all kits. The methods and results
were verified with ddPCR across a wide range of variant characteristics (low VAF, diffi-
cult indels, random SNVs, and VAF influenced by CNA).
Initially, the consortium utilized a wide range of bioinformatic methods to ascertain
the relevant content of the candidate reference samples. We subsequently determined
that the consortium-wide bioinformatic effort could be greatly reproduced by imple-
menting a single high-quality pipeline (such as SomaticSeq) with fewer (two or three)
enrichment kits, but requiring duplicate libraries of sufficient quality, complexity, and
depth. Similarly, duplicate libraries from a small number of enrichment kits can moni-
tor any drift in the cell lines and reference sample to provide quality assurance for fu-
ture batches.
Methods
Library preparation and sequencing of cell lines and Sample A with WES1 (Roche) and
WES2 (IDT) exome kits performed at University of Texas Southwestern Medical Center
and Novogene
All genomic DNA samples were provided by Agilent (Agilent Technologies). Whole ex-
ome sequencing libraries were constructed using KAPA Hyper Prep kit (Kapa Biosys-
tems) and Roche NimbleGen SeqCap EZ hybridization and wash kit (Roche
Sequencing Solutions), or Next Ultra II DNA Library Prep kit for Illumina (New Eng-
land Biolabs) and IDT xGen hybridization and wash kit (Integrated DNA technologies,
Inc.) according to the manufacturers’ instructions. Briefly, genomic DNA was sheared
to an average fragment size of 200 bp or 300 bp on Covaris S220 (Covaris). Ten nano-
grams, for 10 UHR cell lines and Sample B in duplicate, or 100 ng for Sample A in trip-
licate, of fragmented DNA, was used as input for the library preparation. Samples were
sequentially end-repaired, A-tailed, and adapter-ligated. The libraries were then sub-
jected to minimal PCR cycling and quantified with Agilent DNA 1000 assay. One
microgram of each sample library was hybridized with WES1 and 500 ng of each sam-
ple library with WES2. The hybridized probe-target complexes were captured with
streptavidin beads and washed to remove non-targeted DNA. Captured libraries were
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amplified by PCR, and the quality of the libraries was validated by Agilent high sensitiv-
ity DNA assay and quantitative PCR. The libraries from each panel were pooled in
equimolar amounts and subjected to 150-bppaired-end sequencing (PE150) at Novo-
gene on an Illumina HiSeq 4000 for the cell line libraries and on an Illumina HiSeq X
Ten for Sample A libraries.
Library preparation and sequencing of cell lines and Sample A with WES3 (Agilent
SureSelect) exome kits performed at Q2 Solutions/EA Genomics and Novogene
Genomic DNA libraries from individual cell lines blended in Sample A and the final
pooled sample were constructed in duplicate for individual cell lines and in triplicate
for Sample A according to the SureSelectXT Target Enrichment System for Illumina
Paired-End Multiplexed Sequencing workflow at EA Genomics with additional automa-
tion protocol modifications as described elsewhere [48]. In brief, 200 ng of each cell line
high molecular weight genomic DNA was sonicated in a 50 μl total volume in a Covaris
E220 instrument to a mean size of 150 bp (Duty Factor: 10%, Peak Incident Power: 175,
Cycles per Burst: 200, Treatment Time: 2 × 180 s, Bath Temperature: 2° to 8 °C). DNA
fragments were then end-repaired and A-tailed, followed by ligation to XT adaptors for
15 min at 20 °C. Adapter-ligated fragments were amplified by PCR in a 50 μl total vol-
ume with Herculase II Fusion DNA Polymerase under the following conditions: 2 min
at 98 °C (initial denaturation), 10 cycle amplification of 30 s at 98 °C, 30 s at 65 °C, 1
min at 72 °C, and 10min at 72 °C (final extension). Library quality control (concentra-
tion and size distribution) was then assessed using a Picogreen assay and the 2200
TapeStation with D1000 screen tape. In total, 750 ng of prepared gDNA libraries was
then hybridized to SureSelect Human All Exon V6 biotinylated RNA probes for 24 h at
65 °C and captured with Dynabeads MyOne Streptavidin T1 beads. SureSelect enriched
gDNA libraries were PCR amplified and indexed using on-bead protocol in a 50 μl total
volume with Herculase II Fusion DNA Polymerase under the following conditions: 2
min at 98 °C (initial denaturation), 11 cycles of 30 s at 98 °C, 30 s at 57 °C, 1 min at
72 °C (amplification), and 10 min at 72 °C (final extension), followed by 4 °C hold. All
DNA purifications between steps were performed with AMPure XP beads as indicated
in the user manual. Post-capture library quantification was done using qPCR and frag-
ment size distribution determined by HSD1000 screen tape assay on TapeStation 2200.
Indexed libraries were finally pooled and sequenced on either an Illumina HiSeq 2500
or HiSeq X Ten instrument. Individual cell lines were sequenced at EA Genomics to a
200× on-target mean read depth after deduplication on HiSeq 2500 instruments in
high-output mode with V4 sequencing reagents using a 2 × 100 bp paired-end protocol
(Q30 scores ≥ 80%). Pooled Sample A libraries with 200 ng of input were sequenced at
Novogene on a HiSeq X Ten-PE150 with standard workflow (post-deduplication target
depth of 270×, 417×, and 583× using a 2 × 150bp paired-end protocol (Q30 scores ≥
75%).
Library preparation and sequencing of cell lines with WES4 (Thermo Fisher AmpliSeq)
kits performed at Thermo Fisher
The Ion AmpliSeq™ Exome Panel [49] was utilized to generate libraries for next-
generation sequencing on the Ion Torrent S5 platform. The panel contains 293,903
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amplicons in 12 pools. This assay enables analysis of variants across > 97% of the Con-
sensus Coding Sequences (CCDS). Eleven DNA samples (10 human cell lines and one
human reference gDNA) were used to prepare libraries with a mean insert size of 215
bp. Exome libraries were generated following the manufacturer’s instructions in the Ion
AmpliSeq Exome RDY Library Preparation User Guide [50] with 100 ng input for each
sample. Each sample was assigned a distinct IonCode barcode [51]. Each barcoded li-
brary was diluted to 30 pM for template preparation on the Ion Chef™ Instrument using
the Ion 540™ Kit-Chef [52]. Sequencing was performed with the Ion S5™ XL System
[53] and the Ion 540™ Chip [54].
Signal processing and base calling were performed using Torrent Suite Software v5.4
using default parameters for the AmpliSeq Exome assay. The signal processing step
consists of modeling the pH dynamics on the semiconductor surface taking account of
the varying local pH in each individual sensor coming from the different reagent flows
across the chip and from any nucleotide incorporation that may be happening over
each sensor [55]. The base calling step consists of taking the estimated levels of nucleo-
tide incorporation for each read and each nucleotide flow and modeling the de-phasing
process whereby some templates within each clonally amplified population run ahead
or behind in terms of their nucleotide incorporation. During the base calling process,
sample-specific barcodes and 3′ adapters are annotated.
Library preparation and sequencing of WGS1 with 10X Genomics performed at Cornell
University and data analysis at National Heart Lung and Blood Institute
Samples were shipped on dry ice to the HudsonAlpha Institute. Sample aliquots were
profiled for QC on a 0.4% agarose gel with ErBr, run at 58 V for 1.75 h. Libraries of
each sample were synthesized using the 10X Genomics Chromium Genome kit accord-
ing to the manufacturer protocol. Each library was sequenced on one lane of an Illu-
mina HiSeqX. Raw sequence data was demultiplexed and converted to barcode and
read data FASTQ files using 10X Genomics Long Ranger mkfastq version 2.2.1. Align-
ment, deduplication, filtering, and subsequent calling and phasing of SNPs, indels, and
structural variants was achieved for each sample using Long Ranger wgs version 2.2.2,
against both hg19 and GRCh38 reference human genomes retrieved from the 10X Gen-
omics Long Ranger downloader website. Both GATK and FreeBayes variant callers
were employed using Long Ranger alignments for WGS variant analysis.
Agilent analysis of WES3
Each sample was demultiplexed using bcl2fastq with the base mask Y150, I8, Y10,
Y150, and all default settings except for mask-short-adapter-reads, which was set to 0.
Adapters were trimmed using AGeNT Trimmer (Agilent). All data was aligned to the
hg19 reference genome using bwa-mem [29] v1.7.10 with default settings. Quality con-
trol was performed using Picard tools and an internally developed pipeline. Deduplica-
tion was performed with Picard [56] MarkDuplicatesWithMateCigar v2.9.2 with default
settings except for a minimum distance of 500.
Variant calls were done as follows. SureCall v3.5.1.46 (Agilent) was run starting from
aligned files with default settings with two exceptions: the ‘minimum number of reads
supporting variant allele’ was set to 3 and the ‘minimum allele frequency’ value was
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reduced to .001. Samtools calls were completed using samtools [24] v1.3.1 and bcftools
[57] v1.3.1, with commands of the form ‘samtools mpileup -d 8000 -uvf $REF_FASTA
$BAM_FILE | bcftools call -mv | bcftools view -O v’. Platypus calls were completed
using platypus [23] v0.8.1 and using default settings. GATK [58] Unified Genotyper
v2.2–3 were run with default settings, except the filter filterMBQ was applied and
dbSNP v147 was used as a reference.
Roche analysis of WES1, WES2, and WES3
The FASTQ files from the WES1 dataset are quality checked with FastQC [59] to en-
sure the sequencing quality. Adapters were trimmed using AlienTrimmer [60]. The
reads were then mapped to reference genome hg38 and hg19 with bwa-mem [29]
(v0.7.12 (RSSMSN01-RSSMSN04)). Samtools [24] fixmate tool was applied to correct
any read-pairing issues that may be introduced by bwa. Duplicated reads were marked
with Picard [56] MarkDuplicates, and base quality score was recalibrated with GATK
[58] BaseRecalibrator and ApplyBQSR. The processed BAM files were then supplied to
four variant callers, i.e., GATK mutect2 (v2.1-beta/v 4.0 alpha), Vardict (v1.5.1), sam-
tools mpileup (v1.2), and Sentieon TNscope [25] (201,704.03).
For the WES1, WES2 and WES3 datasets run with the RSSMSN05 and RSSMSN06
pipelines, a similar analysis was performed, but the mapping step to hg38 was done
with bwa-mem [29] (v0.7.17). The processed BAM files were supplied to GATK [58]
mutect2 (v 4.0.6.0) using default settings and GATK HaplotypeCaller (v 4.0.6.0) for
variant calling.
National Center for Toxicological Research (NCTR) analysis of WES1, WES2, and WES3
The NCTR team’s pipelines were applied on WES1, WES2, and WES3 datasets. Refer-
ence genomes were downloaded from Illumina iGenomes website for both hg19 and
hg38 version. Reads were aligned with BWA-MEM [29] (v0.7.12-r1039) and Bowtie2
[31] (v2.3.2). Duplicate reads were marked using Picard [56] (v2.7.1) MarkDuplicates
function. The reads were then local realigned around small insertions and deletions
(indels) and base quality scores were recalibrated using GATK [58] (v3.6-0-g89b7209).
dbSNP (b150) was supplied to GATK for indel realignment and quality score recalibra-
tion. GATK’s default downsampling option was suspended by setting “--downsam-
pling_type NONE.” Variants were called with FreeBayes [21] (v1.1.0-46-g8d2b3a0) and
VarScan2 [61] (v2.4.0) with their default settings.
National Institute for Environmental Health Sciences (NIEHS) analysis of WES1, WES2, and
WES3
The NIEHS team’s pipeline was applied to WES1, WES2, and WES3 datasets. Raw data
from the FASTQ files was preprocessed with cutadapt [62] (v. 1.12) by removing the
sequencing adapter and low quality read (Q20), then was aligned to human reference
genome (hg19) with BWA-MEM [29] (v0.7.15-r1140) with default parameters (bwa
mem -M -t 4 -a -V -T 60 -p). The alignment was post-processed with Picard [56]
(v2.9.1) by removing the duplication, then bam files for each tissue were merged (by ex-
ome capture vendor platform library). All three batches of whole exome sequencing
alignments have gone through an in-houseEnsemble-Variant-Calling pipeline, which
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contains Samtools [24] (v1.3.1.), Mutect1 [22] (v1.1.4), and VarScan2 [61] (v2.4.3), and
the calling was done with default recommended parameters. Whenever the reference
genome was needed for variant calling, hg19 was used for WES1, WES2, and WES3.
Human SNPs obtained from dbSNP v.146 were used in the variant calling to mask
germline variants. Somatic variants were reported according to each exome capture
platform vender’s recommended filtering criteria and in conjunction with a minimum
read depth of 20.
Instituto de Genetica Medica y Molecular (INGEMM) analysis of WES1
The INGEMM team’s pipeline follows best practices of GATK version 3.3–0. First, the
FASTQ files were preprocessed with trimommatic [63] v0.32. Then, the filtered se-
quences were mapped to the UCSC human reference genome hg19 (version February
2009) with Bowtie2 [31]. Duplicate reads were removed using Picard [56] RemoveDu-
plicated function. Indel realignment and base quality score recalibration was performed
afterwards (RealignerTargetCreator and IndelRealigner functions from the suite GATK
[58]). Variant calling was performed over the realigned and recalibrated BAM files. The
variants characterized were the result of in-house consensus criteria between the out-
puts of the GATK variant callers UnifiedGenotyper and HaplotypeCaller. The consen-
sus VCF files were filtered and annotated with Annovar [64]. In addition, the vcf file
was enriched with prediction tools of pathogenicity provided by the proxy dbNSFP [65]
(v3.0) together with population data (Exac Non-Finnish European data [66], clinical
and genomic information).
The quality of library amplification and the sequencing procedure was assessed by a
range of markers such as the percentage of mapped reads, the percentage of mapped
reads in the region of interest (ROI), the percentage of duplicated reads, and the per-
centage of ROI over a depth of 20× (i.e., horizontal coverage). Also, the final efficiency
of each sample was measured by the ratio of the sequences that are able for variant de-
termination and the initial number of mapped reads.
Finally, the mean depth and the horizontal coverage together with a set of markers
was evaluated to establish if the samples were suitable for the study. For that, each sam-
ple was flagged with any of the three statuses: Ok, warning, or rejection.
Q2 solutions/EA genomics analysis of WES1, WES2, and WES3
WES1, WES2, and WES3 for individual cell lines were aligned with BWA-MEM [29]
(v0.7.10) using hg19 reference sequence and local alignment was done with ABRA [67]
(v0.94). Alignment was replicates for hg38 but for WES1 only. Deduplication was per-
formed with Picard [56] (v1.140). Variants were called with VarDict [26] (v1.5.1) and
Sentieon [68] TNscope (v201704) (http://www.sentieon.com/). Similarly, variants were
called on Sample A using the same methods. Separately, WES3 cell line variants were
also called for hg19 only with GATK HaplotypeCaller (v3.6–0). All results were output
as VCF (v4.2). In addition, for some analyses, CNAs were called for WES3 with Covit
(in-house tool) and CNV Radar [69] (in-house tool).
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Fondazione Bruno Kessler (FBK) analysis of WES2
Multiple lanes of the same replicate were merged into a single FASTQ file before read
trimming with SeqPurge [70] (version 0.1-886-gf72a054) and alignment on hg19 with
HISAT2 [71] (v2.0.4). At each analysis step, FastQC [59] (v0.11.5) was used to check for
quality and processing progress. Variants were called using Platypus [23] (v0.8.1). We note
that duplicate reads were not removed prior to variant calling, as Platypus directly dedu-
plicates BAM files during the calling process. BCFtools [57] (v1.9-207-g2299ab6) was used
for variant annotation, filtering and selection. tabix (v1.6) and RTGtools [72] (v3.8.4) were
used to manipulate the VCF files and compute basic statistics.
University of Fudan analysis of WES1, WES2, and WES3
Reference genome hg38 was used for all work. Reads were mapped with BWA [29]
(v0.7.12-r1039). Variants were called with Sentieon Haplotyper (v201611.02). CNV esti-
mation from WGS data was done with Breakdancer [73] (v1.1), CNVnator [74] (v0.3.3),
Delly2 [75], DWAC-Seq(v0.7), GenomeSTRiP [76] (v2.0), Meerkat [77](v0.189),
MetaSV [78] (v0.5.2), read depth (v0.9.8.4), svclassify [79], and Pindel [80] (v0.2.0).
CNV estimation for the WES datasets was performed with CNVkit [81] (v0.8.5),
CODEX [82] (v1.6.0), CopywriteR [83] (v2.6.0), DeAnnCNV [84], EXCAVATOR2 [85]
(v1.1.2), ExomeDepth [86] (v1.1.10), GATK [58] 4 Alpha, RefCNV [87], SAAS-CNV
[88] (v0.3.4), and VarScan2 [61] (v2.4.2). All results were output as VCF files.
Thermo Fisher analysis of WES4
After completion of primary analysis with Torrent Suite [89] v5.4, reads were uploaded
to Ion Reporter [90] v5.6 for subsequent processing. Reads were aligned with tmap
[91], which uses the BWA fastmap routine to map reads and applies post-processing of
the alignments to optimize for technology-specific error patterns. After alignment, vari-
ant calling was performed with Torrent Variant Caller (TVC) [92], a variant calling
framework optimized for Ion Torrent data. TVC takes as input the aligned reads and
uses a modified version of Freebayes to generate a very permissive list of candidate de
novo alleles to be evaluated. The de novo alleles are evaluated in a statistical likelihood
model that compares the observed flow signals for all of the aligned reads with the flow
signals that would be expected under reference and non-reference hypotheses. The use
of flow signals leads to significant improvements in variant calling compared to variant
calling approaches that rely on base calls alone. At each position evaluated, the poster-
ior likelihood of each evaluated allele’s frequency is assessed to determine if the null hy-
pothesis that the allele frequency is less than or equal to a particular threshold can be
rejected. Finally, a series of post-calling filters are applied to variant calls to filter out
situations where the statistical model of flow signals is not a good fit for the observed
data, and to eliminate potential artifacts where a variant appears on only one strand in
regions with coverage on both strands, or in only one amplicon in regions where more
than one amplicon spans the variant.
CN analysis of individual cell lines
The CN analysis of individual cell lines to assess the level of chromosomal alterations
individual cell lines was performed using the GenetiSure Cancer Research CHG + SNP
Jones et al. Genome Biology          (2021) 22:111 Page 24 of 38
microarray. Another method used WES3 VAF and relative depth profile data (WES3
had highest average depth of the WES kits) to illustrate certain ploidy-level characteris-
tics of specific cell lines as shown in Additional file 2: Fig. S3.
The GenetiSure Cancer Research CGH + SNP Microarray, 2 × 400 K (Agilent,
G5975A), used in this study contains approximately 300,000 CGH probes and 120,000
SNP probes. Many of CGH probes are targeted to cancer regions of the genome with
median CGH probe spacing of 10 kb in the targeted cancer regions. CN changes (am-
plifications and deletions) are measured using three or more CGH probes for almost
90% of the covered exons, providing resolution down to the single exon level. Percent
of CNAs in each individual UHR cell line was estimated using the CytoGenomics soft-
ware v 4.0.
DNA samples were prepared using the SureTaq complete DNA labeling kit (Agilent,
PN 5190-4240) as described in the Agilent Oligonucleotide Array-Based CGH for Gen-
omic DNA Analysis Protocol (Version 7.5 June 2016). One microgram of each DNA
sample was enzymatically digested and then labeled with Cy5 or Cy3 dyes. Ten individ-
ual UHR DNA samples labeled with Cy5 were hybridized against sex-matched refer-
ence samples labeled with Cy3. Samples were hybridized to the GenetiSure Cancer
Research CGH + SNP Microarray, 2 × 400 K for 40 h at 67 °C, then washed, scanned
using the SureScan scanner, and analyzed using the CytoGenomics software v 4.0.
QC analysis of the Sample A individual libraries
FastQC [59] v0.11.6 was used to determine the quality of the demultiplexed FASTQ
files. Each sample in each lane was downsampled to 120 million read pairs using SeqTK
v1.0 and mapped using bwa-mem [29] v0.7.15 with default parameters. Reads from 5
different lanes were merged using Picard [56] v2.9.0 MergeSamFiles. To assess the li-
brary size and percent duplication, duplicates reads were identified with Picard v2.9.0
MarkDuplicates. Duplicate marked BAM files were used to evaluate target enrichment
using Picard v2.9.0 HsMetrics.
In silico Sample A methods (confirmation)
For each WES kit, we prepared the in silico Sample A by combining reads from all cell
lines. For each cell line replicate, we aligned and marked the duplicated reads using Pic-
ard [56] MarkDuplicates. Then, we mixed the deduplicated alignments of all cell line
replicates, followed by GATK [58] IndelRealigner and Base Quality Score Recalibration
(BQSR) steps on the mixed alignment for the derived in silico Sample A. We then used
SomaticSeq [28] in tumor-only mode to combine somatic mutation predictions from
six individual somatic mutation callers, Strelka2 [93], MuTect2 [94], VarScan2 [61],
VarDict [26], LoFreq [95], and Scalpel [96] on this sample. Scalpel only detects INDELs
and the other five callers detect both SNVs and INDELs. Mutations with ≥ 3 supports
were included in the final output. The VAF for the reported calls are computed using
the minimum mapping quality of 1 and the minimum base quality of 5.
Merged-BAM Sample A methods (confirmation)
For each WES kit, we prepared the merged-BAM Sample A by combining aligned reads
from different libraries of pooled Sample A. Each pooled Sample A library was aligned
Jones et al. Genome Biology          (2021) 22:111 Page 25 of 38
and deduplicated separately using Picard [56] MarkDuplicates. Then, we mixed the
deduplicated alignments, followed by GATK [58] IndelRealigner and BQSR steps on
the mixed alignment to obtain the merged library A alignment. Using SomaticSeq [28]
in tumor-only mode, we then combined predictions from six individual somatic muta-
tion callers, Strelka2 [93], MuTect2 [94], VarScan2 [61], VarDict [26], LoFreq [95], and
Scalpel [96] on this merged library. Scalpel only detects INDELs and the other five cal-
lers detect both SNVs and INDELs. Mutations with ≥ 3 supports were used for assess-
ment. The VAF for the reported calls are computed using the minimum mapping
quality of 1 and the minimum base quality of 5.
NIST high-confidence regions (v3.3.2 benchmark regions)
As described in the main text, NIST has, through their Genome-in-a-bottle (GIAB)
program, made available at ftp://ftp-trace.ncbi.nlm.nih.gov/giab/ftp/release/ variants
and high-confidence genomic calling regions for (at the time) five distinct persons.
High confidence for GIAB samples was achieved by several methods, of which the ini-
tial primary results were from determining consensus among distinct library preps (in-
cluding 10X Chromium preps), sequencing, (e.g., sequencing platforms typically
involved Illumina, Ion Torrent, and SOLID), and variant calling methods. The genome
HG001 (aka NA12878), had additional data from more sequencing platforms and add-
itional review to identify extended regions from the initial consensus for what was
viewed as “high-confidence” calls for that genome. Due to this special case of additional
data and review of the high-confidence regions, the SEQC2 consortium instead exam-
ined the high-confidence regions for HG002, HG003, HG004, and HG005 (all v3.3.2)
and their overlap for hg19 and hg38, respectively. The overlap in high-confidence re-
gions between any pair of this set was greater than 95% while the overlap in high confi-
dence of any member of the set with HG001 was usually less than 91% of HG001 due
to its much larger size and that HG001 includes chrX while the others did not. The
final region selected as the high-confidence region for this study for the individual cell
lines and their mixture was the intersection of the high-confidence regions of HG002-
HG005. Although we performed parallel discovery and validation for hg19 and hg38,
the positives are primarily determined using the high-confidence region of hg19 as
hg38 is noticeably smaller in size.
Human exome
Human genome annotation files were downloaded from Ensembl FTP site. For hg19,
gtf file was downloaded on August 23, 2017 from ftp://ftp.ensembl.org/pub/release-75/
gtf/homo_sapiens /Homo_sapiens.GRCh37.75.gtf.gz. For hg38, gff3 file was downloaded
from ftp://ftp.ensembl.org/pub/ release-97/gtf/homo_sapiens/Homo_sapiens.GRCh38.
97.gtf.gz on September 22, 2019. The exon regions of major chromosomes (chr1-22,
chrX, chrY, and chrM) were extracted and saved as BED files for both versions
accordingly.
Human coding regions
Human coding regions were downloaded from UCSC. In UCSC Table Browser, we
chose “Feb. 2009 (GRCh37/hg19)” for assembly, “Genes and Gene Predictions” for
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group, “NCBI RefSeq” for track, and “UCSC RefSeq (refGene)” for table. We chose
“BED” as the output format and then clicked “get output”. We chose “Coding Exons”
and clicked “get BED.” We performed the same procedure for hg38. The Coding BED
file for hg19 was retrieved on August 23, 2017, and the hg38 version was retrieved on
September 22, 2019. Both files can be downloaded from our data repository [97] at fig-
share. To further restrict the human coding regions, we only took the intersection be-
tween UCSC Coding regions and the Ensembl Exon regions.
Low complexity regions
Low complexity regions were identified using an implementation of sdust [32] from
https://github.com/lh3/minimap2, utilizing default parameters (-w 64 -t 20). The entire
hg19 or hg38 genome file was processed to produce a bed file. Low complexity regions
which overlapped with Ensembl Exon regions (GRCh37-75 for hg19 and GRCh38-97
for hg38) were extracted using bedtools [98] intersect. 5-nt was padded to both ends of
each interval.
Consensus target region
The consensus target region (CTR) [97] is primarily defined by the intersection of (i)
the Interval4 regions, (ii) the human coding regions, and (iii) the NIST high-confidence
regions. Interval4 is simply the intersection of the targeted design regions for WES1–4.
CTR was generated for both hg19 and hg38. The targeted regions for WES1, which
were designed in hg38, were lifted over to hg19 using the UCSC LiftOver tool. The tar-
geted regions for WES2–4, which were designed in hg19, were lifted over to hg38. Fi-
nally, the low complexity regions were excluded. The size of CTR is 22,694,348 in hg19
and 21,710,990 in hg38 and shown in comparison to other regions of interest in Add-
itional fie1; Table S2.
Rules for determining Class 1 positive variants (by each genome version)
There were a diversity of variant calling pipelines used by members of the SEQC con-
sortium. We asked the bioinformaticians of each organization to develop their pre-
ferred pipelines with their best expertise to call variants on their selected WES and
WGS datasets. For WES datasets, there were twenty-two pipelines developed by nine
teams as shown in Additional file 1: Table S3. All teams selected certain WES datasets
for which they had their best experience. Each WES1–3 dataset was analyzed by seven
to fourteen different pipelines on either reference genome versions. All teams selected
certain WES datasets for which they had their best experience. Each WES1–3 dataset
was analyzed by seven to fourteen different pipelines on either reference genome
versions.
The freedom of choice of datasets, reference genome versions, mappers, and callers
as well as parameters and filters created diversity and resulted in marginal to signifi-
cantly different results between variant calling pipelines on the same input data. We in-
vestigated the similarity of the pipeline-library combinations (PLCs) in terms of variant
calling on the individual UHR cell lines. The results did not fall into simple patterns.
Many PLCs provided quite similar variant calls while outlier pipelines were also
detected.
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To achieve consensus, we defined a Class 1 positive variant as having at least half of
the PLCs call the variant with alternative allele frequency (VAF) no less than 10% on
the same cell line for each of WES1–3. The variant list for each cell line was then
pooled together across the cell lines by kit to generate a non-redundant list of variants
for the pooled Sample A by kit. We then took the intersection of the non-redundant
variants called for each of WES1, WES2, and WES3 to compose the Class 1 list of vari-
ants, which are defined as known positives in this study. We also considered the region
for which we would define the Class 1 variants. Only variants called within the CTR
were termed as Class 1 known positives. We performed this procedure for hg19 then
conducted a liftover for mapping to hg38 genome positions.
The Class 1 positives are not a complete list of variants for pooled Sample A. How-
ever, given (i) the large sequencing depth, (ii) only variants with VAF ≥ 10% were con-
sidered by cell line, (iii) the variants were selected by voting with multiple PLCs with
diversity of callers and also agreed among three WES datasets, and (iv) a random sam-
ple of 114 (including 33 at VAF < 5%) of these variants were 100% orthogonally verified
by ddPCR, we consider the Class 1 variants to be known positives.
Rules for determining Class 2 positive variants
Variants from WGS 10X Chromium libraries of individual cell lines were examined in
high-confidence coding regions of COSMIC genes but outside of CTR regions that in-
cludes common design coding regions to all WES kits utilized in this study. If the same
variant was called by two different WGS variant callers (Freebayes and GATK) and was
called by SomaticSeq from two different WES kits in the same cell line, then the variant
was categorized as a Class 2 positive variant. The magnitude of the Class 2 positives
was much smaller (by two orders of magnitude) than those of the Class 1 positives
(359 vs. 42,211). This is primarily due to Class 2 positives being restricted to COSMIC
genes and from the WES kits having highly overlapping target regions, which exclude
these loci from being considered as a Class 2 variant. However, the number of Class 2
positives in COSMIC genes with VAF < 20% (210) is more than 10% of the identified
total positives with VAF < 20% in COSMIC genes (1653).
Complex variants including multi-allelic variants and multi-nucleotide variants (MNVs)
Particular attention should be paid to complex variants as there is typically variability
in the manner in which they are documented. For example, we detected 32 loci that
had distinct alternative alleles between various cell lines. When pooled into Sample A,
these will appear as multi-allelic variants. For simplicity for analytical performance cal-
culations and given the small magnitude of these variants, they were removed from our
official positive variant list. However, we are quite confident in our assessment that
these 32 loci are multi-allelic in Sample A and those 32 loci (64 variants) are provided
in Additional file 1: Table S11. In addition to multi-allelic variants, we have also docu-
mented certain SNVs/indels in phase with other SNVs/indels which could be properly
termed MNVs. Our list of positives includes over 200 dinucleotide and some trinucleo-
tide positions that can more properly be termed as MNVs as well as other potential
MNVs.
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When evaluating the performance of cancer panels, it is important that proper guide-
lines and tools be used relative to the known content of complex reference samples
[99]. We recommend using tools such as RTG vcfeval when reviewing panel results
with Sample A positives to resolve the ambiguities with multiple representation of vari-
ants so that false positive and false negatives are best characterized.
Rules for determining known negative variant positions
In addition to known positives, we also determined a set of negative positions. The total
read depth (DP), reference allele depth (RDP) and alternative allele depth (ADP) were
counted with the samtools [24] (v1.9) mpileup function at each position. Positions with
DP < 50 in one library were removed. DP and RDP of the two libraries for each cell line
were summed together and the reference allele frequency (RF), alternative allele fre-
quency (AF) recalculated. We then applied filters by merged DP ≥ 125 and recalculated
RF ≥ 99%. A simple averaged RF of the ten cell lines was calculated and filtered by aver-
age RF ≥ 99.5%. We only considered negative positions inside the CTR (which is a sub-
set of the intersection of the coding target regions for the WES1–3) as used for the
Class 1 positives. We did this procedure for both genome versions hg19 and hg38. We
then lifted over the hg19 version to hg38 (noted “hg19ToHg38”) and hg38 version to
hg19 (noted “hg38ToHg19”) with R package rtracklayer [100] (v1.42.0). For INDEL
calls with the simple samtools mpileup, the adjacent positions from both ends of the
INDEL calls were removed. To further remove possible variants, we employed a similar
route to call negative positions through WES1–3 data of pooled Sample A. The DP and
RDP of all libraries of each of WES1–3 were summed together. Any positions with total
DP ≥ 500, ADP > 2, and AF ≥ 0.002 were removed. The adjacent positions from both
ends of the INDEL calls were also removed. Finally, we took the intersection between
hg19 and hg38ToHg19, or between hg38 and hg19ToHg38 as known negatives for the
pooled Sample A in this study. This stringent process led to 10,229,649 negative posi-
tions in hg19 and 10,208,086 negative positions in hg38.
ddPCR methods (orthogonal validation)
Droplet digital PCR (ddPCR) technology uses water-oil emulsion to partition the DNA
sample into thousands of nanoliter-sized droplets and thus generates thousands of
measurement data points for independent PCR amplification event [101]. We chose
Bio-Rad’s PrimerPCR™ Assays for ddPCR as a proven technology for orthogonal valid-
ation to NGS with a convenient pipeline for custom assay design. Given a 100 ng DNA
sample, PrimerPCR assays accurately detect mutant DNA in 10,000-fold wild type
background (Bio-Rad Droplet Digital PCR Application Guide).
In total, 375 targets were selected for ddPCR validation and testing. These targets
represented multiple variants variant types such as Class 1 and Class 2 positive variants,
known negatives, and some investigational loci. SNVs, indels, and variants under influ-
ence of CN variation were examples of variant types. We established three criteria to
guide the process of target selection: (i) preference was given to targets with clinical
relevance or those in cancer related genes such as COSMIC genes; (ii) stratification
with random selection: a sufficient number of targets were assigned to each category
and then targets were randomly selected within each category; (iii) targets with close-by
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variant(s) were avoided in order to minimize interference with the primer or probe of
the ddPCR assay. Mapped COSMIC IDs or sequence around the target were used as
the input for online assay design. Only targets with a successful assay design were kept
for further consideration. The assays and their categories are listed in Additional file 1:
Table S12. Below is the description and count of assays in each category.
Category 0: Variants with documented oncology relevance. Subset 0.1 includes 19
hotspot variants detected in cell lines or Sample A (investigational). Subset 0.2 includes
39 targets which are known negatives. Subset 0.3 includes 9 investigational targets as
putative negatives.
Category 1: Class 1 variants (SNV or small indels) in 219 COSMIC Classic genes.
Out of 340 designable targets, 132 variants were randomly selected. Seventeen assays
were excluded due to design errors discovered after the fact. As a result, there were
115 assays randomly selected as Class 1 variants from COSMIC genes.
Category 2: Class 2 variants (SNV or indels) in COSMIC genes. From 359 Class 2
variant targets, 50 variants were selected for ddPCR assay design, all in COSMIC genes
as all Class 2 variants are in COSMIC genes.
Category 3: Low VAF Class 1 variants. These variants have VAF in Sample A ranging
from 1 to 2.5%. This category includes 40 positives that are present in only one cell line
that is not BLY and then 10 variants that are present only in BLY.
Category 4: Challenging and other indels. All candidate indels were first called in
WES data and confirmed by 10X Genomics WGS data. Indels longer than 20 bps could
not be designed. Out of all designable indels, 50 indels were randomly chosen with one
design failure leaving 49 ddPCR assays for indels. Challenging indels included 14 indels
that were low frequency (i.e., VAF < 10%), 8 complex (insertion or deletion at least 2
bases in length), and 20 that were both. In addition, there were 7 additional simple
Indels.
Category 5: Variants under greater CN influence. A list of about 40 potential candi-
dates was first generated for 13 regions under CN influence in various individual cell
lines. At least one designable variant was then manually chosen to represent each re-
gion. For certain wide regions, two variants were chosen. In total, there were 20 Class 1
positives assayed by ddPCR under greater CN influence.
Category 6: Additional investigational low VAF variants (not Class 1 or Class 2)
called by Accugenomics pipeline [102] that incorporate the background sequencing
error rate inferred from Accugenomics controls. Potential variants were reported in
two pan-cancer panels from the Pan-Cancercross-lab study [102] using Sample A.
There were 24 investigational ddPCR assays in this category.
Each ddPCR assay was used to test gDNA from 10 individual UHR cell lines and ref-
erence Samples A, B, C, D, and E. The sample input amount for 10 UHR cell lines and
Sample A was 11 ng. The input amount was chosen to enable variant allele detection
sensitivity of 0.1% while moderately conserving samples. Eight assays and 11 samples
were multiplexed to a 96-well plate with one well for a no-template control (NTC)
sample for each assay. The input amount was increased to 55 ng for more sensitive de-
tection in reference Samples B, C, D, and E. To ensure the results were reproducible,
Samples B, D, and E were tested in duplicate wells. Twelve assays and four samples (oc-
cupying seven wells) were multiplexed to a 96-well plate with one well for an NTC
sample for each assay. In total, 84 plates were used to implement the whole ddPCR
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experiment. Following Bio-Rad’s ddPCR protocol, samples were first fragmented by the
enzyme specified in each assay design and loaded to the QX200™ AutoDG instrument
(Bio-Rad) for analysis. Data analysis was then carried out through Bio-Rad’s software
with the users manually checking and, if necessary, adjusting cluster thresholds for each
assay. After clustering, the magnitude of group cluster membership of individual drop-
lets (negative for both alleles, allele1 occupancy, allele2 occupancy, occupancy by both
alleles) was evaluated for consistency with expected values from binomial distribution
assumptions related to joint probabilities for distinct alleles occupying the same drop-
let, single alleles occupying a droplet and for neither allele occupying a droplet. Incon-
sistencies were corrected and assays not achieving expected distributional frequencies
were deemed as failed. A description of the loci tested by ddPCR is also provided in
Additional file 1: Table S12.
Analysis of cell line mixture proportions
In principle, it should be possible to calculate/estimate the theoretical allele frequencies
in Sample A for each of the variants identified in the individual cell lines starting from
the allele frequencies and/or the read counts at a locus determined independently for
each cell line. This would provide evidence that the mixtures were performed properly
and are at expected levels in the pooled final reference. We attempted to build models
that used read counts in each cell line related to known positives to predict their VAF
by locus in Sample A. VAFs calculated on the deeply sequenced sample A were used to
estimate the error of the prediction. To simplify analysis and given the abundance of
variants available, we identified private known positives by cell line and performed a
linear regression tuned on the private known positives so that the VAF from positives
of Sample A could be expressed as a linear combination of the cell line VAFs (positive
or 0). The model multipliers were obtained by solving the linear system whose matrix
is computed as the convex combination of the depth and the alternate allele counts on
a chosen subset of all possible genomic positions. While some models appeared more
reasonable than others, we observed large variations in the β estimates for the cell line
mix ratios for different models and subsets, resulting in fundamentally unreliable VAF
predictions. The instability in estimates was possibly due to the large number of rear-
rangements in the cancer cell lines, creating inconsistent depth at a given locus from
cell line to cell line. A simple linear regression of the VAF of each cell line onto the
Sample A VAF provided reasonable if oversimplified results that indicated the cell lines
were properly mixed (given the approximate 1:2 mixture of TLY into BLY described
elsewhere).
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value) of the WES4 panel on individual cell line variants. Fig. S3. TLY VAF profile at top where common variants
from dbSNP are in red (het) or green (hom). Variants not found in dbSNP are in orange. Since TLY has an
asymmetric VAF profile indicated in by the somatic variants in orange, the reasonable explanation (combined with
cytology) is that TLY is inherently tetraploid with some noticeable large sCNA (e.g., chr 4, 7, 8, 17 and 20 are most
noteworthy) and that the somatic variants are all near 0.25 as somatic changes are randomly scattered among the
two chromosome pairs from the cancer cell, rarely affecting both. In essence, cell line TLY is a fusion of a normal
and cancerous cell. Fig. S4. VAF histogram of Sample A for Class 2 variants only (COSMIC genes but not in CTR).
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1 positives are > 99% of all positives. k-t) Histograms of VAF using only Class 2 positives contributed by each of the
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library results and the averaging of individual cell line results. Results between same kits are slightly more highly
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A using only the single SomaticSeq pipeline. Only 0.24% are not detected by SomaticSeq in either in silico Sample
A or merged-BAM Sample A. Fig. S8. CN and other data establishing BLY as a mixture of original BLY and TLY. VAF
profile at top consists of only common SNPs as well as the log ratio of TLY and BLY depths (compared to normal
reference Sample B). The green regions indicate TLY somatic CN loss and the red regions indicate TLY somatic CN
gain. Gray regions are somatic CN gain or loss examples that only exist in BLY and thus must have come from the
original B lymphocyte cell line. All TLY gains and losses clearly appear exactly in BLY except for the gain in chr4.
Thus, the original B lymphocyte cell line must have a corresponding chr4 loss, which was verified by subsequent
CNV analysis of the original B lymphocyte cell line (data not shown). Fig. S9. Each point is a putative variant either
associated with canonical het and homozygous non-reference alleles (blue), putative variants with replicated non-
zero VAF but outside canonical regions (red), or putative variants observed in only one replicate (gray). The repli-
cate VAF of the Normal B Reference cell line is shown for the Q201 pipeline for all variants in coding regions (top)
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error. Fig. S10. As a supplement to Fig. 3a, this figure illustrates the difference observed in VAF between ddPCR and
consensus WES results across a range of VAF and different types of variants tested by ddPCR. One can see the bias
in the VAF estimate from WES and how it is more pronounced at higher VAF values and for indels vs. SNVs. Fig.
S11. Results from a series of simulations using 2 to 12 independent unrelated cell lines from 13 cell line candidates
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and simulating VAF and number of variants using a mixture of a random subset of them. The yellow line indicates
the median of the typical VAF given the various mixtures of cell lines. The orange dashed lines indicate the median
of the 25th (Q1) and 75th (Q3) percentiles of the VAF given the various mixtures of the cell lines. The solid blue
lines indicate the median total coding variants that one could identify in the CTR while the dashed blue line indi-
cates the typical (median) total number of coding variants that one expects to have an allele frequency less than
10%. Corresponding values observed for Sample A are also shown.
Additional file 3. Supplementary information. Bias in reported WES allele frequencies. Recommended process for
reference sample creation.
Additional file 4. Review history.
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